Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis

Study Title
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Teva Identifier
ALS-GA-201
ClinicalTrials.gov Identifier
NCT00326625
Study Status
Completed
Trial Condition(s)
Amyotrophic Lateral Sclerosis
Interventions
Drug: 40 mg glatiramer acetate | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 70 Years
Trial Duration
July 31, 2006 - July 31, 2008
Phase
Phase 2

Study Type

Interventional